Dr. Jeremy B. Desai has been appointed president and chief executive officer of Apotex replacing Jack Kay, who will serve as vice chairman of the board.
Dr. Desai has 30 years of pharmaceutical experience having held numerous senior positions. Dr. Desai has been with Apotex for the past 11 years, most recently serving as president and chief operating officer, and executive vice president and global head of R&D.
Apotex is among the largest Canadian pharmaceutical companies with more than 5,500 employees in Canada and 10,000 globally. It has exports to 75 countries with planned R&D expenditures of $2.1 billion within the next 10 years.